IRIS
PARISI, Alessandro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.507
AS - Asia 2.080
EU - Europa 1.196
SA - Sud America 466
AF - Africa 85
OC - Oceania 4
Totale 6.338
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.411
SG - Singapore 617
VN - Vietnam 497
CN - Cina 387
IT - Italia 372
BR - Brasile 349
RU - Federazione Russa 336
HK - Hong Kong 292
FR - Francia 126
DE - Germania 89
IN - India 65
BD - Bangladesh 54
GB - Regno Unito 54
FI - Finlandia 47
MX - Messico 42
NL - Olanda 40
AR - Argentina 38
CA - Canada 37
IE - Irlanda 35
IQ - Iraq 24
CI - Costa d'Avorio 22
AT - Austria 21
EC - Ecuador 21
ID - Indonesia 20
ZA - Sudafrica 20
CO - Colombia 17
SE - Svezia 16
ES - Italia 15
PK - Pakistan 15
JP - Giappone 14
VE - Venezuela 13
KR - Corea 12
PL - Polonia 10
SA - Arabia Saudita 10
MA - Marocco 9
TR - Turchia 9
CL - Cile 8
EG - Egitto 8
PH - Filippine 8
PY - Paraguay 8
AE - Emirati Arabi Uniti 7
PE - Perù 7
UA - Ucraina 7
KE - Kenya 6
LT - Lituania 6
TW - Taiwan 6
DZ - Algeria 5
TH - Thailandia 5
TN - Tunisia 5
UZ - Uzbekistan 5
AU - Australia 4
BG - Bulgaria 4
CR - Costa Rica 4
IL - Israele 4
KZ - Kazakistan 4
LB - Libano 4
PA - Panama 4
AZ - Azerbaigian 3
BY - Bielorussia 3
JO - Giordania 3
NG - Nigeria 3
NP - Nepal 3
PR - Porto Rico 3
UY - Uruguay 3
AL - Albania 2
BO - Bolivia 2
JM - Giamaica 2
QA - Qatar 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
AW - Aruba 1
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BH - Bahrain 1
CH - Svizzera 1
CY - Cipro 1
CZ - Repubblica Ceca 1
ET - Etiopia 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
IR - Iran 1
KG - Kirghizistan 1
KW - Kuwait 1
LY - Libia 1
MM - Myanmar 1
MU - Mauritius 1
MY - Malesia 1
MZ - Mozambico 1
OM - Oman 1
PT - Portogallo 1
RO - Romania 1
SI - Slovenia 1
SN - Senegal 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TG - Togo 1
ZW - Zimbabwe 1
Totale 6.338
Salva come PNG Salva come JPEG
Città #
Ashburn 742
San Jose 350
Singapore 347
Hong Kong 284
Council Bluffs 217
Ho Chi Minh City 175
Dallas 169
Hanoi 109
Beijing 100
Boardman 89
Lauterbourg 71
Los Angeles 68
The Dalles 66
Hefei 61
Moscow 52
Milan 41
Munich 41
Helsinki 36
Orem 35
Dublin 33
São Paulo 33
New York 32
Santa Clara 32
Buffalo 26
Da Nang 24
Mexico City 24
Rome 24
Shenzhen 24
Abidjan 22
Chennai 21
Nuremberg 19
Ancona 18
Chicago 18
Chandler 17
Montreal 17
Fairfield 15
Haiphong 14
London 14
Houston 13
Shanghai 13
Seattle 12
Tokyo 12
Zhengzhou 12
Brasília 11
Camerino 11
Denver 11
Vienna 11
Amsterdam 10
Des Moines 10
Jacksonville 10
Miano 10
Turku 10
Washington 10
Bologna 9
Hải Dương 9
Manchester 9
Warsaw 9
Can Tho 8
Frankfurt am Main 8
New Delhi 8
Rio de Janeiro 8
Urbisaglia 8
Ann Arbor 7
Biên Hòa 7
Boston 7
Dhaka 7
Elk Grove Village 7
Florence 7
Johannesburg 7
Lima 7
Naples 7
Ninh Bình 7
Stockholm 7
Toronto 7
Atlanta 6
Baghdad 6
Bari 6
Bogotá 6
Erbil 6
Guangzhou 6
Medellín 6
Phoenix 6
Quito 6
Secaucus 6
Thái Bình 6
Asunción 5
Campinas 5
Cotia 5
Goiânia 5
Guayaquil 5
Lawrence 5
Louisville 5
Matelica 5
Miami 5
Mumbai 5
Nairobi 5
Porto Alegre 5
Princeton 5
Saint Louis 5
Salt Lake City 5
Totale 3.947
Salva come PNG Salva come JPEG
Nome #
Adjuvant treatment with Capecitabine in patients who received orthotopic liver transplantation with incidental diagnosis of intrahepatic cholangiocarcinoma. Implications on DPYD polymorphisms assessment: report of two cases and review of the literature 196
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 158
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 132
Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status 129
Concurrent RAS and RAS/BRAF V600E Variants in Colorectal Cancer: More Frequent Than Expected? A Case Report 126
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry 122
Pemigatinib in pazienti affetti da colangiocarcinoma localmente avanzato o metastatico con fusione o riarrangiamento di FGFR2 pretrattati: analisi congiunta degli studi di coorte multicentrici, osservazionali, "real-world" francese PEMI-BIL e italiano PEMI-REAL 117
Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis 112
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 110
Comparison of different second line treatments for metastatic pancreatic cancer: a systematic review and network meta-analysis 109
The PERSONS score: A new tool for cancer patients' symptom assessment in simultaneous care and home care settings 107
COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry 106
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 105
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 102
Current Evidence and Future Perspectives about the Role of PARP Inhibitors in the Treatment of Thoracic Cancers 100
Communication in oncology between healthcare providers, patients, the scientific community, and the media: recommendations from the Italian Association of Medical Oncology (AIOM) 99
A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement? 99
First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience 96
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer 96
Immunotherapy in Triple-Negative Breast Cancer 93
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study 92
Comparison Between First Line Target Therapy and Immunotherapy in Different Prognostic Categories of BRAF Mutant Metastatic Melanoma Patients: An Italian Melanoma Intergroup Study 92
Changes in clinical presentation, management, and survival outcomes in patients affected by colorectal cancer following COVID-19 pandemic 88
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study 88
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer 88
Conversion Strategy in Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer Patients with Unresectable Liver-Limited Disease: A Multicenter Cohort Study 87
The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference 85
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study 85
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies 84
COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry 83
Multimodality treatment in metastatic gastric cancer: From past to next future 82
Evaluation of prognostic factors for survival in transverse colon cancer 82
Aflibercept-Based and Bevacizumab-Based Second Line Regimens in Patients with Metastatic Colorectal Cancer: Propensity Score Weighted-Analysis from a Multicenter Cohort 81
What is known about theragnostic strategies in colorectal cancer 81
MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)–Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors—A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study 81
Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study 80
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study 78
The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer 77
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: A retrospective multicenter study 77
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 76
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 76
How to best exploit immunotherapeutics in advanced gastric cancer: Between biomarkers and novel cell-based approaches 75
Timed-flat infusion of 5-fluorouracil with docetaxel and oxaliplatin as first-line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen 75
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population 74
Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry 74
Is it a new era for intrahepatic cholangiocarcinoma? 72
Bone recurrence in early breast cancer patients: The paradox of aromatase inhibitors induced bone resorption 72
Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study 71
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction 71
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer 71
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab 71
The dynamics of circulating tumour DNA (ctDNA) during treatment reflects tumour response in advanced melanoma patients 68
Post-induction Strategies in Metastatic Colorectal Cancer Patients Treated With First-Line Anti-EGFR-Based Treatment: A Systematic Review and Meta-Analysis 66
The emerging role of immunotherapy in the treatment of anal cancer 65
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: Preliminary report of the FAMI-L1 study 62
A case of segmental hepatic necrosis complicating oxaliplatin and capecitabine chemotherapy: A case report and review of the literature 61
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience 60
Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: An update from clinical practice 59
Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A “snapshot” from clinical practice 58
The PERSONS score for symptoms assessment in simultaneous care setting: A pilot study 58
Immune Checkpoint Inhibitors and Myasthenic Syndromes: A Case Report of a Metastatic Renal Cell Carcinoma Patient Treated With Nivolumab 58
Haloperidol for the treatment of opioid addiction in advanced cancer patients: a case series 57
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 57
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study 57
Time-Dependent COVID-19 Mortality in Patients with Cancer: An Updated Analysis of the OnCovid Registry 57
Family History of Cancer as Potential Prognostic Factor in Stage III Colorectal Cancer: a Retrospective Monoinstitutional Study 55
Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature 54
The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A ‘hypothesis-generator’ study from clinical practice 53
Looking for a place for dose-dense TMZ regimens in GBM patients: An experience with MGMT exploratory evaluation 52
Topical menthol for treatment of chemotherapy-induced peripheral neuropathy 51
Expression of pro-angiogenic factors as potential biomarkers in experimental models of colon cancer 50
SEX-RELATED DIFFERENCES IN EFFICACY AND SAFETY OF IMMUNOTHERAPY IN HEPATOCELLULAR CARCINOMA: SYSTEMATIC REVIEW AND META-ANALYSIS OF LANDMARK PHASE III TRIALS AND VALIDATION IN ROUTINE CLINICAL PRACTICE 50
Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain–Barré Syndrome 49
Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A “hypothesis-generator” preliminary report 48
Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy 48
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 48
Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study 47
Where are we with treatment options after first line in small cell lung cancer?-Report of two opposite cases treated with CAPTEM regimen and possible perspectives 46
Into the storms: Organising oncological home care services during natural disasters and global pandemics 40
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab 38
Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis 38
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 33
SHORT-COURSE RADIOTHERAPY FOR OLDER PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER AND UNFIT FOR CHEMOTHERAPY: THE SOFT STUDY 32
The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort study 30
Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and Durvalumab 25
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population 20
Clinically interpretable nomogram combining body composition and clinicopathological features for one year survival prediction in advanced solid tumors 13
Preliminary report on advanced biliary cancer patients receiving multimodality treatment in the immunotherapy era: a real-world multicentre experience 13
Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study 10
Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study 7
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma 6
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinoma 4
Totale 6.586
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.357
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.357
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202231 0 2 0 0 0 2 1 1 13 1 6 5
2022/202371 5 3 4 10 0 11 0 2 18 7 10 1
2023/2024254 16 3 13 19 18 27 2 13 1 71 25 46
2024/20251.356 151 76 42 12 39 50 200 67 274 96 115 234
2025/20264.568 213 343 198 478 337 303 849 436 469 494 248 200
2026/2027263 263 0 0 0 0 0 0 0 0 0 0 0
Totale 6.586